DSIP (Delta Sleep-Inducing Peptide)

Overview

DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during sleep-related electrophysiology research in the 1970s. Despite the name, its role in normal human sleep physiology remains genuinely unresolved — a 2006 review is literally titled "Delta sleep-inducing peptide (DSIP): a still unresolved riddle."

Proposed Mechanism of Action

DSIP's mechanism is not well characterized. Endogenous plasma DSIP follows a diurnal rhythm (peaking mid-afternoon, lowest around 1 AM in one study), and levels are reported to correlate negatively with REM and slow-wave sleep — but a causal mechanism for exogenous DSIP's reported sleep effects has not been firmly established in the literature we reviewed.

Research Context

The cited 1981 trial is small (6 healthy volunteers) but well-controlled (double-blind crossover), and found that intravenous DSIP increased daytime sleep pressure and improved several measures of subsequent nighttime sleep. Critically, this is not the whole picture: other published trials in chronic insomniacs report far more modest or statistically marginal effects, and at least one study concluded that short-term DSIP treatment "is not likely to be of major therapeutic benefit" for chronic insomnia. We chose to cite the strongest-effect study here, but the broader literature is mixed — see the "Limitations" section below before treating DSIP as a well-established sleep aid.

Limitations of the Current Evidence

• Human trials are small and decades old; several show only marginal or inconsistent effects, and the compound's basic mechanism of action remains unresolved as of recent reviews.
• Trials generally used intravenous administration in clinical settings — this does not reflect how DSIP is typically sold or used outside of research (e.g., subcutaneous injection), and no cited study here establishes dosing or efficacy for that route.